



A survey of metastasis suppressors in Metazoa

Helena Četković¹ · Matija Harcet¹ · Maša Roller² · Maja Herak Bosnar³

Received: 20 May 2017 / Revised: 4 January 2018 / Accepted: 18 January 2018 / Published online: 16 February 2018
© United States & Canadian Academy of Pathology 2018

Abstract

Metastasis suppressors are genes/proteins involved in regulation of one or more steps of the metastatic cascade while having little or no effect on tumor growth. The list of putative metastasis suppressors is constantly increasing although thorough understanding of their biochemical mechanism(s) and evolutionary history is still lacking. Little is known about tumor-related genes in invertebrates, especially non-bilaterians and unicellular relatives of animals. However, in the last few years we have been witnessing a growing interest in this subject since it has been shown that many disease-related genes are already present in simple non-bilateral animals and even in their unicellular relatives. Studying human diseases using simpler organisms that may better represent the ancestral conditions in which the specific disease-related genes appeared could provide better understanding of how those genes function. This review represents a compilation of published literature and our bioinformatics analysis to gain a general insight into the evolutionary history of metastasis-suppressor genes in animals (Metazoa). Our survey suggests that metastasis-suppressor genes emerged in three different periods in the evolution of Metazoa: before the origin of metazoans, with the emergence of first animals and at the origin of vertebrates.

Introduction

It is well known that cancer patients rarely die from the original disease but are usually victims of its dissemination to distant body sites. In this process, cancer cells undergo a series of events usually termed the invasion-metastasis cascade [1]. In order to inhabit new locations, metastatic cells must physically detach from the main tissue (tumor cell dissociation), break through the basal lamina and invade the surrounding tissue (invasion), enter the nearby blood or lymphatic vessels (intravasation), survive the

transit through the lymphatic or blood system, and extravasate from blood/lymphatic vessels into distant tissue (invasion). In distant locations, metastatic cells can form small cellular clusters, which eventually grow into macroscopic tumors (colonization) [2]. Metazoans (animals) are built as complex structures, typically organized into tissues and organs, where every cell is committed to the wellbeing of the whole organism. Processes such as growth or cell migration are strictly controlled. Metazoan organism developed a series of defense mechanisms against non-cooperating cheater cells, such as apoptosis. Tumor (metastatic) cells are often destroyed by turbulences within the vascular system, get trapped in small vessels, or attacked by the immune system [3]. In order to disseminate, cancer cells have to acquire the capacity to invade the surrounding tissue and move into the circulatory system. The survival in the distant unfamiliar environment and, often, unrelated tissue is especially challenging and requires cellular transcriptional reprogramming which leads to major phenotypical changes usually called epithelial to mesenchymal transition (EMT) [4]. The precise nature of the changes that occur in the metastatic process on the molecular level is still quite unclear. The discovery of genes/proteins that are directly involved in the metastatic cascade is a big step forward in our understanding of this process. The group of metastasis-suppressor proteins was established in 1988 after the identification of NME using differential hybridization analysis

These authors contributed equally: Helena Četković and Matija Harcet.

Electronic supplementary material The online version of this article (<https://doi.org/10.1038/s41374-018-0024-9>) contains supplementary material, which is available to authorized users.

✉ Maja Herak Bosnar
mherak@irb.hr

¹ Laboratory for Molecular Genetics, Division of Molecular Biology, Ruđer Bošković Institute, Bijenička 54, Zagreb, Croatia

² Division of Molecular Biology, Department of Biology, Faculty of Science, University of Zagreb, Horvatovac 102A, Zagreb, Croatia

³ Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička 54, Zagreb, Croatia

Table 1 Metastasis suppressors in humans (updated and adapted from refs. 7, 32, 44, 99)

Metastasis suppressors	Gene ensemble ID	Proposed biochemical and biological function	Intracellular localization	Implicated metastasis step
AKAP12	ENSG00000131016	Scaffold for protein kinases, protein binding, regulated Src, PKC and Rho signaling, VEGF secretion	Cytoskeleton, cytoplasm, focal adhesion, plasma membrane	Angiogenesis, migration
ARHGDI2	ENSG00000111348	Regulates Rho GTPases, cytoskeletal remodeling, GTPase activity, GTPase activator activity	Cytoplasm, cytoskeleton, extracellular	Migration, colonization
Rho GDP dissociation inhibitor beta	ENSG00000174744	Transcriptional regulation, chromatin modifying protein, reduce phosphoinositide signaling and restore gap junction communication	Nucleus	Invasion, transport, colonization
BRMS1	ENSG00000182985	Protein binding, cytoskeletal remodeling, cell cycle arrest, apoptosis and invasion	Membrane, extracellular	Colonization
Breast cancer metastasis suppressor 1	ENSG00000064012	Protein binding, stress-activated protease (apoptosis related), cell cycle arrest	Cytoplasm, nucleus, plasma membrane	Survival, transport, invasion, colonization
CADM1	ENSG00000105974	Scaffolding protein, protein binding, links integrins to tyrosine kinase FYN-activation of signaling through Ras-Raf-MEK-Erk, altering caveolae function	Membrane (caveolae), Golgi apparatus, endosome, endoplasmic reticulum	Invasion (intravasation/extravasation), possibly colonization
Cell adhesion molecule 1	ENSG00000026508	Transmembrane glycoprotein adhesion molecule, cell-cell and cell-matrix adhesion	Membrane, extracellular, Golgi apparatus	Migration
CASP8	ENSG00000085117	Protein binding, induces apoptosis, regulates TIMPs, stabilizes adherens junction	Plasma membrane, extracellular	Intravasation, transport
Caspase-8	ENSG00000039068	Protein binding cell-cell adhesion	Membrane-extracellular, Golgi, endosome	EMT, invasion
CAVI	ENSG00000140937	Cell-cell adhesion	Plasma membrane, extracellular	Tumor cell dissociation, intravasation, migration
Caveolin-1	ENSG00000170558	Cell-cell and cell-matrix adhesion	Plasma membrane, extracellular	Tumor cell dissociation (local invasion), intravasation
CD44	ENSG00000121552	Protease binding cathepsin inhibitor	Extracellular, plasma membrane, nucleus, cytosol	Angiogenesis, migration, invasion
CD44 molecule (Indian blood group)	ENSG00000187323	Protein binding, regulates MAPK signaling; cytoskeletal remodeling; regulates cell cycle arrest and apoptosis	Plasma membrane	Transport, migration, invasion
CD82	ENSG00000164741	Rho GTPase activator activity, cytoskeletal remodeling	Cytoskeleton, cytosol, nucleus, plasma membrane	Migration, invasion
CD82 molecule	ENSG00000113657	Protein binding, cytoskeletal remodeling	Cytoskeleton, cytosol	Invasion
CDH1				
Cadherin 1				
CDH11				
Cadherin 11				
CDH2				
Cadherin 2				
CSTA				
Cystatin A				
DCC				
DCC netrin 1 receptor				
DLC1				
DLC1 rho GTPase-activating protein				
DPYSL3				
Dihydropyrimidinase like 3				

Table 1 (continued)

Metastasis suppressors	Gene ensembl ID	Proposed biochemical and biological function	Intracellular localization	Implicated metastasis step
DRG1 Developmentally regulated GTP binding protein 1	ENSG00000185721	GTP binding, promotes cell differentiation, upregulates E-cadherin and inhibits EMT	Cytoplasmic/nuclear upon DNA damage	Angiogenesis, invasion, colonization
GAS1 Growth arrest specific 1	ENSG00000180447	Protein binding, cell cycle arrest, apoptosis	Membrane	Colonization
GPR68 G protein-coupled receptor 68	ENSG00000119714	G protein-coupled receptor activity (proton sensing receptor)	Plasma membrane	Migration
GSN Gelsolin	ENSG00000148180	Protein (actin, myosin II) binding, cytoskeletal remodeling, inhibits EMT	Cytosol, cytoskeleton, plasma membrane, extracellular	Migration
HUNK Hormonally upregulated Neu-associated kinase	ENSG00000142149	Protein kinase, cytoskeletal remodeling	Cytosol, nucleus	Migration, invasion
KDM1A Lysine demethylase 1A	ENSG00000004487	Protein and DNA binding, chromatin remodeling, histone demethylase activity	Nuclear	Invasion
KISS1 KISS-1 metastasis suppressor	ENSG00000170498	Ligand for G-protein receptor (Kiss receptor), angiogenesis	Extracellular (secretion)	Colonization, angiogenesis
KLF17 Kruppel like factor 17	ENSG00000171872	DNA binding, transcriptional factor	Nucleus	Invasion
LIFR Leukemia inhibitory factor receptor alpha	ENSG00000113594	Protein binding, signaling molecule, ciliary neurotrophic factor receptor binding	Plasma membrane, extracellular	Migration, invasion, colonization
MAP2K4 Mitogen-activated protein kinase kinase 4	ENSG00000065559	Stress-activated protein kinase	Cytosol, nucleus	Migration, colonization
MAP2K7 Mitogen-activated protein kinase kinase 7	ENSG00000076984	Stress-activated protein kinase	Cytosol, nucleus	Migration, colonization
MAPK14 Mitogen-activated protein kinase 14 (p38)	ENSG00000112062	Stress-activated protein kinase	Cytosol, extracellular, nucleus	Colonization
MTBP MDM2 Binding protein	ENSG00000172167	Protein binding, cell cycle arrest, cytoskeleton remodeling	Cytosol, nucleus	Invasion

Table 1 (continued)

Metastasis suppressors	Gene ensembl ID	Proposed biochemical and biological function	Intracellular localization	Implicated metastasis step
NME1	ENSG00000239672	Nucleotide binding, NDP kinase, protein kinase, protein scaffold, cellular nucleotide pool maintenance	Cytosol, nucleus, plasma membrane, extracellular	Migration, colonization
NME/NM23 nucleoside diphosphate kinase 1				
NR1H4	ENSG00000012504	DNA binding, transcriptional factor activity, lipid and glucose metabolism, promote apoptosis	Nucleus	Invasion, colonization
Nuclear receptor subfamily 1 group H member 4				
PEBP1	ENSG00000089220	Protein binding, nucleotide binding, Raf1 kinase inhibitor, inhibits MEK phosphorylation, cytoskeletal remodeling	Cytosol, nucleus, extracellular	Migration, invasion
Phosphatidyethanolamine binding protein 1				
RRM1	ENSG00000167325	Protein binding, ribonucleoside-diphosphate reductase activity, cytoskeletal remodeling	Cytosol, nucleus, extracellular	Migration, invasion
Ribonucleotide reductase catalytic subunit M1				
TIMP1	ENSG00000102265	Protease binding, inhibit MMP expression and signaling	Extracellular (secretion)	Angiogenesis, migration, invasion, transport
TIMP metalloproteinase inhibitor 1				
TIMP2	ENSG00000035862	Protease binding, inhibit MMP expression and signaling	Extracellular (secretion)	Angiogenesis, migration, invasion, transport
TIMP metalloproteinase inhibitor 3				
TIMP3	ENSG00000100234	Protease binding, inhibit MMP expression and signaling	Extracellular (secretion)	Angiogenesis, migration, invasion, transport
TIMP metalloproteinase inhibitor 3				
TIMP4	ENSG00000157150	Protease binding, inhibit MMP expression and signaling	Extracellular (secretion)	Angiogenesis, migration, invasion, transport
TIMP metalloproteinase inhibitor 4				

Symbols and gene names are obtained from HUGO Name Gene Nomenclature Committee (HGNC), whereas the information on intracellular localization is obtained from GeneCards®: The Human Gene Database

Table 2 Representative organisms used for cross-species analysis

Organism	Short code	Common name	Taxonomy	Assembly version	Data source
<i>Capsaspora owczarzaki</i> ATCC 30864	Cowc	Ameba	Filasterea	C_owczarzaki_V2	Ensembl Genomes
<i>Monosiga brevicollis</i>	Mbre	Choanoflagellate	Choanoflagellata	Monbr1	JGI
<i>Amphimedon queenslandica</i>	Aque	Sponge	Porifera	Aqui1	Ensembl Genomes
<i>Trichoplax adhaerens</i>	Tadh	Trichoplax	Placozoa	ASMI5027v1	Ensembl Genomes
<i>Mnemiopsis leidyi</i>	Mlei	Comb jelly	Ctenophora	GCA_000226015.1	Ensembl Genomes
<i>Nematostella vectensis</i>	Nvec	Sea anemone	Cnidaria	GCA_000209225.1	Ensembl Genomes
<i>Hydra vulgaris</i>	Hvul	Polyp	Cnidaria	GCA_000004095.1	NCBI
<i>Schistosoma mansoni</i>	Sman	Flatworm	Platyhelminthes	ASM23792v2	Ensembl Genomes
<i>Capitella teleta</i>	Ctel	Ringed worm	Annelida	GCA_000328365.1	Ensembl Genomes
<i>Crassostrea gigas</i>	Cgig	Seashell	Mollusca	GCA_000297895.1	Ensembl Genomes
<i>Caenorhabditis elegans</i>	Cele	Round worm	Nematoda	WBcel235	Ensembl Genomes
<i>Drosophila melanogaster</i>	Dmel	Insect	Arthropoda	BDGP6	Ensembl Genomes
<i>Stegodyphus mimosarum</i>	Smim	Spider	Arthropoda	GCA_000611955.2	Ensembl Genomes
<i>Strongylocentrotus purpuratus</i>	Spur	Sea urchin	Echinodermata	GCA_000002235.2	Ensembl Genomes
<i>Saccoglossus kowalevskii</i>	Skow	Acorn worm	Hemichordata	Skow_1.1	NCBI
<i>Ciona intestinalis</i>	Cint	Sea squirt	Urochordata	GCA_000224145.1	Ensembl
<i>Branchiostoma belcheri</i>	Bbel	Lancelet	Cephalochordata	GCA_001625305.1	NCBI
<i>Petromyzon marinus</i>	Pmar	Lamprey	Vertebrata/Cyclostomata	Pmarinus_7.0	Ensembl
<i>Danio rerio</i>	Drer	Fish	Vertebrata/ Osteichthyes	GRCz10 (GCA_000002035.3)	Ensembl
<i>Xenopus tropicalis</i>	Xtro	Frog	Vertebrata/Amphibia	JGI 4.2	Ensembl
<i>Anolis carolinensis</i>	Acar	Lizard	Vertebrata/Reptilia	AnoCar2.0	Ensembl
<i>Gallus gallus</i>	Ggal	Bird	Vertebrata/Aves	Gallus_gallus-5.0	Ensembl
<i>Ornithorynchus anatinus</i>	Oana	Platypus	Vertebrata/Mammalia/Prototheria	OANA5 (GCF_000002275.2)	Ensembl
<i>Monodelphis domestica</i>	Mdom	Opossum	Vertebrata/Mammalia/Metatheria	monDom5	Ensembl
<i>Mus musculus</i>	Mmus	Mouse	Vertebrata/Mammalia/Rodentia	GRCm38.p5	Ensembl
<i>Macaca mulatta</i>	Mmul	Monkey	Vertebrata/Cercopithecoidea	Mmul_8.0.1 (GCA_000772875.3)	Ensembl
<i>Homo sapiens</i>	Hsap	Human	Vertebrata/Homimidae	GRCCh38.p7	Ensembl

of murine K-1735 cells of different metastatic potential [5]. Metastasis suppressors are specifically involved in regulation of one or several steps of the metastatic cascade. Their expression in the primary tumor is, in general, lower than in the corresponding metastasis. The key feature of a metastasis-suppressor gene is that its expression inhibits metastasis but it normally does not influence primary tumor growth. Upon restoration of its function, the cell is no longer metastatic although it remains tumorigenic [6]. Metastasis suppressors vary in their subcellular localization and have diverse functions in the cell spanning from protein kinases (MAP2K4, MAP2K7, MAPK14) or nucleoside diphosphate kinases (NME), to cell–cell adhesion molecules such as cadherins (CDHs), transcription factors (KFL17), scaffolding proteins (AKAP12), and many others [7]. Many metastasis suppressors are multifunctional proteins. One or several of their functions can be involved in metastasis suppression. The suppression activity of a specific metastasis suppressor depends on the tumor type. Furthermore, it is possible that a specific protein acts as a metastasis suppressor in one, and as a tumor suppressor or even promotes tumorigenesis in another tumor [8].

The goal of this paper is to give a general overview of the evolutionary history of known metastasis-suppressor genes/proteins in animals and to put it into the context of what is already known about the emergence of neoplasms in animal history. Herein we use the term metastasis suppressor both for the genes/proteins whose metastasis suppression activity is documented (usually in mammals) and for their homologs across metazoans. Whether those genes have similar properties and function in other animal lineages, especially in simple animals such as sponges and cnidarians, or even unicellular organisms, is largely unknown. Given the fact that the published data on the evolutionary history of metastasis suppressors are scarce, we performed an additional bioinformatics analysis to identify homologs of human metastasis suppressor genes in the genomes of animals from diverse lineages, and in closest unicellular relatives of animals (choanoflagellate *Monosiga brevicollis* and filasterean *Capsaspora owczarzaki*). The information obtained was used to complement the available literature on this topic. In addition, we attempted to correlate the appearance of a certain metastasis suppressor gene or a group of metastasis suppressor genes with its biochemical/biological function, localization and/or step in the metastatic cascade in which it is implicated. The list of metastasis suppressor genes/proteins we investigated is available in Table 1. The list of species we chose for our analysis, their phylogenetic relationships, common names, and taxonomic groups to which they belong are displayed in Table 2 and Fig. 1. The distribution of metastasis suppressor homologs across the studied species, as identified by our analysis, is shown in Fig. 2 and Supplementary Figure 1.




Fig. 1 The schematic phylogenetic tree among species we analyzed and taxonomic groups to which they belong

Bioinformatics analysis

Data

Species for the comparative analysis (Table 2; Fig. 1) were chosen to sample key branches of the metazoan phylogeny and for the completion of their genomes. Full proteomes of representative species with whole genome assemblies were downloaded from Ensembl release 87 [9] or from Ensembl Genomes release 34 [10] (Table 2). For those species not represented in Ensembl or Ensembl Genomes, full genomes and proteomes were downloaded from the NCBI's genome database [11] or, if also unavailable there, the JGI portal [12]. The proteomes of each species were filtered to include only the longest protein product per gene, i.e., to eliminate all but one isoform per gene, using a custom Perl script. Custom Perl scripts will be made freely available upon request.

Homologous groups of proteins

The sampling of species in this study is not represented in publicly available database of homologies, so we applied a




Fig. 2 The number of homologs of metastasis related genes is variable across species. The heatmap shows the number of gene homologs to human metastasis related genes across all studied species

computational pipeline to assign all the genes of our selected species to homology groups. Our method for determining homology groups is analogous to the approach used by many others, including EnsemblCompara [13] and OrthoMCL [14]. To assign genes to homologous groups, the filtered proteomes from all species were compared in an all-to-all blastp search using an *e*-value cutoff of $1e-5$ with NCBI's BLAST version 2.4.0+ [15]. The BLAST similarity scores were represented as a graph using an implementation of the MCL algorithm [16], with the program mcxload and the options `--stream-mirror --stream-neg-log10 --stream-tf 'ceil[200]`'. This graph method based on similarity as estimated by BLAST scores allows for the inclusion of more distantly related genes. This makes it more advantageous to a BLAST-only method, especially in finding homologs in more distantly related species. Clusters were extracted from the network using the program mcl with the clustering parameter (-I) set to 3.0.

Extracting homologs groups of metastasis suppressor genes

Clusters of homologous genes were filtered to extract those clusters that contain a homolog to known human metastasis suppressor genes (Table 1). The resulting counts of homologous genes per organism were plotted in R version 3.2.5 [17] with the heatmap.2 function from the gplots package [18].

The presence of homologs of known human metastasis suppressor genes across metazoans is displayed in Fig. 2 and Supplementary Figure 1.

Interpretation of the results

Our approach does not have the power to distinguish between speciation or duplication events in the history of the genes, i.e. it cannot distinguish between orthologs and

paralogs. Therefore, the resulting clusters can only be considered homologs. Furthermore, this approach does not allow a detailed reconstruction of evolutionary histories of each metastasis suppressor family. This is especially true for genes that have patchy distribution across metazoan lineages (Fig. 2; Supplementary Figure 1). The absence of a homolog in a genome assembly could mean that it has been lost in a lineage. However, it can also be a consequence of incomplete genomic information due to limits or errors in sequencing, assembly, or annotation techniques.

Metastasis suppressors that appeared before the origin of animals

According to our analysis and previous work [19], the most prominent period of emergence of metastasis suppressors was before the origin of animals. Most of these proteins, such as MAP2Ks, MAPK14 or NME are important for basic cellular processes common to all living beings (Table 1). We found homologs of these genes in the genome assemblies of all or most animal species we checked (Table 2; Fig. 1), and in, at least, one of their unicellular relatives, as shown in Fig. 2.

NME1

NME1, also known as nucleoside-diphosphate kinase A, is the first identified member of the *NME* family, and the first described metastasis suppressor gene in many different tumor types [20, 21]. *NME1*'s biochemical and biological properties have been extensively investigated over the last two decades, mostly in vertebrates. Besides its role in the maintenance of the cellular (d)NTP pool it seems to have other biochemical functions such as histidine kinase activity, transcription factor activity etc. [22, 23]. It is still unclear which of the functions is responsible for its metastasis suppression activity. The evolution of the *NME* is a rare example of a gene/protein family that has been thoroughly studied [24–28], and it appears to be rather complex. Members of the *NME* family are present in all three domains of life: Bacteria, Archaea, and Eukarya. *NME1* belongs to the *NME* Group I proteins that are highly conserved within the group and between different species. All of the *NME* Group I proteins possess NDP kinase activity. Group I *NME* genes/proteins encompass four paralogs in human, *NME1–4*. Group I *NME1/2* and *NME3/4* genes emerged from an ancestor gene common to all chordates through the first round of whole genome duplication, occurring early in the vertebrate lineage. *NME1* and *NME2* split by *cis*-duplication after the emergence of amphibians [24]. The sponge homolog NMEGp1Sd shows similar biochemical properties to human *NME1* and has the

potential to modulate migratory properties of human tumor cells [26]. Similar results were recently reported for a Group I *NME* homolog from a unicellular eukaryote related to animals, *C. owczarzaki*, Filasterea (Ćetković et al., this issue). Therefore, we presume that the ancestral metazoan *NME* gene/protein was structurally and functionally similar to the sponge *NME* and its human homologs *NME1/2*. In our previous work, we speculated that *NME* in the sponge has the same biochemical function that is responsible for metastasis suppression in human, and was probably established in the ancestor of all metazoans [26] (Ćetković et al., this issue). Homologs of *NME1* were present in the genome assemblies of all organisms we analyzed, from unicellular holozoans to human, with a varying number of homologs per species, which is probably a consequence of lineage-specific duplications, gene losses or incomplete genomic information.

ARHGDIB

Rho GDP dissociation inhibitor beta, is a member of a large family of proteins that regulate guanine nucleotide signaling. It was originally implicated in bladder carcinoma metastasis suppression, but it is involved in other cancer types as well [29]. It has been suggested that this protein is important for modulating tumor microenvironment [30]. We found *ARHGDIB* homologs in all analyzed organisms, from unicellular holozoans to human, except lamprey *Petromyzon marinus* (Vertebrata/Cyclostomata) and spider *Stegodyphus mimosarum* (Arthropoda). There was usually only one or up to four homologs present in each species.

BRMS1

Breast cancer metastasis suppressor 1 is expressed as a 246 amino acid protein in human and is reported to suppress metastasis in breast [31], but also in several other cancer types [32]. *BRMS1* has been described in many species such as the fruit fly *Drosophila melanogaster* and different vertebrates [33]. It was found in the genome assemblies of all organisms analyzed except in the choanoflagellate *M. brevicollis*, the nematode worm *Caenorhabditis elegans* and the Pacific oyster *Crassostrea gigas*.

DPYSL3

Dihydropyrimidinase like 3 was identified as a metastasis suppressor in prostate cancer and is a member of a large family of colapsins [34]. Colapsins regulate axon guidance and neurite outgrowth as well as migration processes [35]. It was present in the genome assemblies of all organisms

analyzed except in the choanoflagellate *M. brevicollis* and the ctenophore *Mnemiopsis leidyi*.

DRG1

Developmentally regulated GTP-binding protein 1, is a GTP-binding protein that belongs to the DRG family consisting of two members: DRG1 and DRG2. DRG1 seems to be involved in many metastasis-associated signaling pathways consequently altering angiogenesis and possibly colonization. Interestingly, DRG1 was first identified as a tumor suppressor in bladder and pancreatic cancers [36], whereas its metastasis suppressor activity was discovered by further research in breast, prostate, and colon cancer [37]. Homologs (either *DRG1* or *DRG2*) have been found throughout metazoans [38]. In our survey, one to four *DRG1* homologs were found in all analyzed genome assemblies.

RRM1

Ribonucleotide reductase catalytic subunit M1, encodes the regulatory subunit of ribonucleotide reductase and has been described to suppress metastasis in lung adenocarcinoma [39–42]. One to three homologs of this gene were present in all analyzed genome assemblies, from unicellular holozoans to human, but no homolog was found in the genome assembly of the lamprey *P. marinus* (Vertebrata/Cyclostomata).

KDM1A

Lysine demethylase 1A, functions as a metastasis suppressor in breast cancer, where it modulates TGF β signaling and EMT [43]. Moreover, in some other tumors (ovarian, prostate, and colon cancer) its expression leads to poor clinical outcomes [44]. A possible single origin of all *KDM1* histone demethylase genes before the split of major eukaryotic lineages has previously been suggested. The *KDM1* genes are conserved during evolution in both number of homologs and domain structure, although a few duplication events were observed in plants [45]. Our analysis confirmed these findings on metazoans. One to three *KDM1A* homologs were present in all analyzed genome assemblies from unicellular holozoans to human.

MAP2Ks and MAPK14

Mitogen-activated protein kinase kinases (MAP2Ks) are protein kinases that phosphorylate (activate) mitogen-activated protein kinases (MAPKs). MAP2K4 is a dual specificity kinase that suppresses metastasis in prostate and ovarian carcinomas [46], whereas it has an opposite effect

in breast and pancreatic cell lines [47]. MAP2K7, MAP2K6, and MAPK14 have been found to suppress metastasis in prostate and ovarian cancer [48, 49]. Furthermore, it has recently been published that MAPK14 signaling activation in breast cancer cells has an important role in repressing tumor metastasis [50]. As MAP2Ks and MAPKs are involved in many crucial cellular events, such as cell cycle progression and growth arrest, their involvement in metastasis suppression is not surprising. Two to eight *MAP2Ks* homologs were found in all genome assemblies, from close unicellular relatives of animals to human. Homologs of *MAPK14* were also found in all analyzed genome assemblies but the number of homologs was much higher (15–49).

DLC1

Rho GTPase-activating protein was identified in breast cancer using microarray-based transcriptional profiling of cell lines with different metastatic potential [51]. The mechanism of its action is still not quite elucidated, but it seems to have a role in functioning of Rho GTPases [52]. *DLC1* homologs were present in all genome assemblies analyzed.

CD82

The CD82 molecule is a glycoprotein and a member of the tetraspanin superfamily. It was found to inhibit cancer cell migration and invasion [53] and is frequently downregulated in human tumor cell lines [54]. Tetraspanins possess transmembrane domains [55] and are found in evolutionary distant taxa such as animals, protists, plants, and fungi [56, 57]. Our analysis confirms these findings; all analyzed animal genome assemblies contained a large number (13 to 41) of CD82 homologs. The gene was absent from the choanoflagellate *M. brevicollis*, but present in the filasterean *C. owczarzaki*.

KLF17

Krüppel-like factor 17 is a protein family of highly conserved zinc finger transcription factors, which are critical regulators of essential cellular processes, including proliferation, differentiation, apoptosis, and migration [58]. It has been shown that *KLF17* expression is significantly downregulated in primary human breast cancer samples and that the combined expression patterns of *KLF17* and *ID1* (inhibitor of DNA binding 1) can serve as a potential biomarker for lymph node metastasis in breast cancer [59]. *KLF* homologs were present in the genome assemblies of all organisms we analyzed.

HUNK

Hormonally upregulated Neu-associated kinase was identified as a breast cancer metastasis suppressor by blocking actin polymerization which leads to reduced cell motility [60]. A large number of *HUNK* homologs (mostly between 20 and 35) were present in the genome assemblies of all organisms we studied.

GSN

Gelsolin was identified as a metastasis suppressor gene in B16-BL6 mouse melanoma cells [61]. GSN binds actin and consequently changes actin cytoskeletal organization [62], but its role in cancer is controversial. It has been described as a metastasis suppressor in breast, bladder, and gastric carcinoma [63–65] but also as a marker of unfavorable prognosis for colorectal cancer patients [66]. We found two to 14 gelsolin homologs in all the genome assemblies we studied.

CSTA

Cystatin A, was found to suppress metastasis formation in human esophageal squamous cell carcinoma and murine mammary carcinomas [67]. Cystatin A is an endogenous inhibitor of Cathepsin B. The balance between the two molecules regulates invasiveness in tumors. We identified *CSTA* homologs in unicellular relatives of animals, but not in the placozoan *Trichoplax adhaerens*, the nematode *C. elegans*, the fruit fly *D. melanogaster*, the sea squirt *Ciona intestinalis* (Urochordata), and the lamprey *P. marinus* (Vertebrata/Cyclostomata).

Metastasis suppressors that appeared in the early evolution of animals

A number of metastasis suppressor genes seem to appear with the emergence of animals. We identified their homologs in simple non-bilaterians, but not in the closest unicellular relatives of animals (Fig. 2). Although all biochemical functions of these proteins have not yet been completely elucidated, it seems that most of them are involved in cell–cell communication and cell cycle control (Table 1).

PEBP1

The mechanism by which phosphatidylethanolamine binding protein 1 executes his metastasis suppressor role is not yet clear, but it is known to interfere with the Raf/MEK/Erk signaling pathway involved in metastasis formation [68]. PEBP1 acts as a metastasis suppressor in several cancer

model systems [68, 69]. We detected *PEBP1* homologs in non-bilaterians *Amphimedon queenslandica* (Porifera) and *Nematostella vectensis* (Cnidaria), but our analysis did not reveal homologs in *T. adhaerens* (Placozoa) and *M. leidy* (Ctenophora). This suggests that *PEBP1* might have appeared early in the evolution of animals and was subsequently lost in some early-branching lineages, or that some of the genomic information from these early-branching lineages is incomplete.

TIMPs

Tissue inhibitors of metalloproteinase balance the activity of metalloproteinases, enzymes in charge of digesting the extracellular matrix during the process of invasion and penetration into the vascular system [70]. Therefore, TIMPs are considered to have metastasis suppressor potential [71–73]. The human genome assembly has four *TIMP* paralogs (*TIMP-1*, *TIMP-2*, *TIMP-3*, and *TIMP-4*) and they inhibit all known metalloproteinases and several members of the ADAMTS (A disintegrin and metalloproteinase with thrombospondin motifs family of proteinases) [74]. Most vertebrates possess at least one *TIMP* homolog [75]. *TIMPs* among invertebrates display a lower percentage of sequence similarity compared to human *TIMPs* [76]. We found a single *TIMP* homolog in the genome assembly of *D. melanogaster*, as previously reported [77]. In the genome assemblies of Hemichordata (*Saccoglossus kowalevskii*), Nematoda (*C. elegans*), Anellida (*Capitella teleta*), and Platyhelminthes (*S. mansoni*), we did not find *TIMP* homologs. Among the four phyla of early-branching non-bilaterian metazoans, Porifera (*A. queenslandica*) and Ctenophora (*M. leidy*) do not possess *TIMP* homologs. The Placozoa (*T. adhaerens*) genome assembly had a *TIMP* homolog. Within Cnidarians, the genome assembly of *N. vectensis* had four *TIMP* genes while *Hydra vulgaris* had none. Our results indicate that *TIMP* family genes originated during the early evolution of animals, before the appearance of bilateria. If the above genome assemblies are complete, *TIMP* genes might have been lost in some and went through independent duplications in other invertebrate lineages.

CAV1

Caveolin-1 has been described as a tumor suppressor [78, 79], but it has also been shown to reduce metastasis in some other tumor models [80–82]. The mechanism behind its metastasis suppressor activity is still unresolved, but it is probably linked to its involvement in caveolae function and receiving signals from the local microenvironment [7]. The *CAV1* homolog was absent from *A. queenslandica* (Porifera), *H. vulgaris* (Cnidaria), *M. leidy* (Ctenophora) and *S. mansoni* (Platyhelminthes) genome assemblies, but

present in *N. vectensis* (Cnidaria) and *T. adherens* (Placozoa) genome assemblies. *CAVI* was also missing from *D. melanogaster* genomic data. According to our results, *CAVI* probably emerged before the separation of placozoans from Eumetazoa. All other analyzed species possessed one to six *CAVI* homologs. The exception was the Pacific oyster *C. gigas* (Mollusca) with a large number of *CAVI* homologs [21] which might be the result of assembly or annotation errors.

MTBP-MDM2

The MTBP-MDM2 binding protein is a MDM2 interacting partner. Previous research [83] determined that MTBP functions as a metastasis suppressor in the osteosarcoma model system. Our analysis places the origin of *MTBP* in the early history of animals, before the separation of cnidarians and ctenophores. We did not find *MTBP* homologs in flatworm *S. mansoni* (Platyhelminthes), nematode *C. elegans*, or arthropod (*D. melanogaster* and *S. mimosarum*) genome assemblies.

GPR68

GPR68 (G protein-coupled receptor 68) is a metastasis suppressor in prostate cancer [84]. The proposed mechanism of its action is inhibiting cell migration and transendothelial migration through increased expression of Gα1 (guanine nucleotide-binding protein G(i) subunit alpha-1) [85]. *GPR68* probably appeared early in the evolution of animals, as it was present in all analyzed organisms except the sponge *A. queenslandica* and close unicellular relatives of animals. A large number of homologs, up to almost 200, was present in genome assemblies of chordates, whereas other animals usually had up to 50 homologs.

NR1H4

Nuclear receptor subfamily 1 group H member 4, a member of the nuclear hormone receptor superfamily, is predominantly expressed in tissues exposed to high levels of bile acids and has recently been designated as a metastasis suppressor [86]. A *NR1H4* homolog was probably present in the common ancestor of all metazoans. A large number of its homologs—usually more than 20 and sometimes in excess of 100—were present in all animal genome assemblies we analyzed. The genome assemblies of the closest unicellular relatives of animals did not possess *NR1H4* homologs.

CASP8

Loss of caspase-8 enhances the migration potential of neuroblastoma cells and drives the tumor towards

malignancy [87]. Caspases are members of the family of cysteine depended aspartate-directed proteases, which are well known for their critical role in programmed cell death. It seems that its absence provides a survival advantage in metastatic cells [44]. Caspase-8 is specifically involved in the extrinsic apoptotic signaling pathway [88]. Neither apoptosis nor true caspases have been found in Protista, fungi, and plants [89]. According to our analysis, *CASP8* homologs were present in the genome assemblies of all Metazoa, but not in their close unicellular relatives.

DCC

Either loss of heterozygosity or loss of expression of *DCC* (Netrin 1 Receptor) has been reported in many advanced stage tumors: ovarian, breast, colorectal, pancreatic, etc., which implicates its role as a metastasis suppressor gene [44, 90]. *DCC* homologs have been found in genome assemblies of all organisms that we analyzed, except in the choanoflagellate *M. brevicollis* and the filasterean *C. owczarzaki*.

Metastasis suppressors that are a chordate or vertebrate innovation

Several metastasis suppressor genes appeared with the origin of vertebrates or during the early vertebrate radiation. Their homologs are present in all or most vertebrate genome assemblies that we analyzed (Table 2; Fig. 1) and were generally absent from the genome assemblies of invertebrate animals and their closest unicellular relatives (Fig. 2). The only metastasis suppressor whose origins could clearly be traced back to the origin of chordates is E-cadherin (*CDH1*).

CADM1

Cell adhesion molecule 1, which belongs to the immunoglobulin superfamily of proteins, has a role in cell–cell adhesion and is responsible for the adhesive properties of human epithelial cells [91]. Its loss is associated with poor prognosis of breast cancer patients [92]. *CADM1* expression is regulated via hypermethylation of its promoter which in turn leads to the EMT phenotype [93–95]. *CADM1* was present in the last common ancestor of vertebrates. We found a putative homolog in the genome assembly of *S. kowalevskii* (Hemichordata) which could indicate a more ancient origin.

GAS1

Growth arrest specific 1, *GAS1*, was first identified for its metastasis suppression role after genome-wide shRNA screen

in B16-F10 melanoma cells [96]. It seems that it exhibits suppressor activity through regulating apoptosis via Caspase 3 and 9 [97]. *GAS1* is most probably a vertebrate innovation, although our analysis unexpectedly revealed one homolog in the cnidarian *N. vectensis* and the nematode *C. elegans*. The *N. vectensis* candidate homolog had a considerably shorter protein product: 135 aa compared to 200–384 aa in vertebrates. It may contain only a domain of the vertebrate protein, or be a truncated gene due to misassembly or misannotation. The *C. elegans* protein had a full length of 228 aa and is most likely a true homolog.

CD44

The CD44 molecule has a dual role in tumor development as a tumor promoter and a metastasis suppressor [98, 99]. This might be due to the enormous complexity of CD44's mechanisms mediated by posttranslational modifications and involvement in multiple physiological processes in the cell [100, 101] which are not yet understood. CD44 almost always has as a single homolog per vertebrate genome assembly.

AKAP12

AKAP12 is a scaffolding protein that affects multiple steps in metastasis suppression in prostate cancer [102] and melanoma cells [103]. Our analysis suggests that a homolog of the metastasis suppressor *AKAP12* was likely present in the last common ancestor of vertebrates.

LIFR

Leukemia inhibitory factor receptor alpha, LIFR has been described as a metastasis suppressor in breast cancer [104], acting as a downstream target of miR9, a metastasis promoter in breast cancer cells. *LIFR* homologs were present in the common ancestor of bony fishes and tetrapods: amphibians, Reptilia (including birds), and mammals.

KISS1

KISS1 was characterized as a metastasis suppressor gene/protein in 1996 [105]. The transcribed product of *KISS1*, kisspeptin, is a 145 aa peptide which is further processed into shorter, biologically active peptides. One of them, metastin, binds to the G protein-coupled receptor GPR54 (also known as KISS1 receptor—KISS1R), and is believed to be responsible for metastasis suppression [106]. Previously, it has been shown that *KISS1* is missing from genomes of birds [107]. We have confirmed this result and found that it is also absent in the genome assemblies of anole lizard, *Anolis carolinensis*. The distribution of homologs in the genome assemblies of vertebrates that we analyzed indicates that KISS1 appeared in

the common ancestor of tetrapods, and was subsequently lost in the common ancestor of sauropsids (extant Reptilia including birds).

CDHs

Metazoans developed three major cellular junctions that are typically present in vertebrate epithelial tissues. One of them, adherent junctions, seem to be present in all metazoan lineages and is considered to be critical for the maintenance of the tissue architecture of multicellular organisms [108]. Adherent junctions are composed primarily of Type I cadherins—transmembrane glycoproteins that form homotypic complexes. Loss of cadherins (CDHs) occurring during EMT enables cancer cells to detach from the original tissue and start the metastatic process. It is widely accepted that the key molecule in metastasis formation onset is specifically E-cadherin [109]. Cadherins and cadherin-related proteins are found in the entire metazoan kingdom and also in choanoflagellates—the closest unicellular relatives of animals [110]. However, CDH1, CDH2 (Type I), and CDH11 (Type II) cadherins are the only cadherin members known to be involved in metastasis suppression [111]. Our analysis identified four homologs in the urochordate *C. intestinalis* genome assembly, and a large number of homologs in vertebrate genome assemblies. We also detected homologs of Type I and Type II cadherins in the purple sea urchin *Strongylocentrotus purpuratus*, and the spider *S. mimosarum*, which suggests a possible more ancient origin.

Metastasis-suppressor genes have diverse evolutionary histories

Our bioinformatics analysis showed that a number of metastasis suppressors (for example *PEBP1*, *RRM1*, *CSTA* and *ARAHGDIB*) are unexpectedly missing from the genome assemblies of some animals (Fig. 2). In the sea lamprey *P. marinus* (Vertebrata/cyclostomata), this phenomenon is pronounced, and could be a consequence of drastic rearrangements during early embryogenesis of the lamprey *P. marinus* genome in which about 20% of the germline DNA from somatic tissues is shed, and potentially includes the genes we queried. It might also be a technical consequence due to the fact that the lamprey genome is highly repetitive and in parts has very high GC content which makes it difficult to sequence and assemble the genome [112, 113]. In general, not all genomes are equally well sequenced, assembled, annotated or studied. The absence of some metastasis suppressors from the genome assembly of the Pacific oyster *C. gigas*, spider *S. mimosarum*, hemichordate *S. kowalevskii* and other genomes with lower quality assemblies could easily be a result of incomplete genomic

data. On the other hand, the absence of a gene from a genome assembly could also be due to true gene loss in specific lineages. It is known that accelerated evolution and gene loss are prominent in some animal lineages such as those leading to *D. melanogaster* and *C. elegans* [114]. Our results showed that some metastasis suppressor families in either or both of those lineages went through the same processes (*MTBP*, *TIMPs*, *CAVI*, *BRMS1*, and *CSTA*) (Fig. 2). Gene loss has to be taken into account while working on *D. melanogaster* and *C. elegans* model systems. For instance, until recently these organisms were considered to be appropriate models for studying apoptosis. On the basis of experiments on these organisms it was concluded that the extrinsic apoptotic pathway emerged on the level of vertebrates since *C. elegans* and *D. melanogaster* lack components required for this pathway. Surprisingly, recent findings on cnidarians [89, 115] have shown that both apoptotic pathways have ancient origins and were already present in the common ancestor of cnidarians and bilateral animals, more than 550 million years ago [116]. All these findings reiterate the necessity to take evolutionary history into account when interpreting results obtained with model organisms.

The survey of the available literature as well as our analysis suggest that metastasis suppressors emerged at different periods in the evolution of life, with the majority grouped at three points, or peaks, of emergence: the origin of the eukaryotic cell, the emergence of multicellularity and the appearance of vertebrates. This is expected because gene numbers and diversity increased with these important evolutionary events [19, 117, 118]. The most prominent period of emergence of metastasis suppressors seems to have occurred before the origin of animals. The appearance of numerous tumor-related genes at the level of unicellular eukaryotes might seem surprising. However, it becomes understandable as we are discovering that their physiological (versus pathophysiological) functions are connected to core biological processes necessary for the maintenance of every living cell. Our investigation indicates that a large number of metastasis suppressors appeared with the emergence of multicellularity in the animal lineage. Although all biochemical functions of the proteins within this peak are far from being elucidated, according to the present knowledge most of them are involved in cell–cell communication and cell cycle control. Four out of eight suppressors which emerged in parallel with multicellularity, *CASP8*, *CAVI*, *DCC*, *GPR68*, are located at least partly in the membrane, and some have receptor activity (*GPR68* and *DCC*) while several have a role in cell cycle control or apoptosis (*CASP8*, *MTBP*, *NRIH4*, *DCC*). This, however does not come as a surprise. Multicellular organization has clear advantages; it allows the specialization of cells for specific functions, and the formation of tissues and organs,

as well as a larger size of the organism. Aktipis and coworkers defined key foundations of multicellularity which include: controlled proliferation, controlled cell death, division of labor, specialized systems for transport of oxygen and nutrients, and extracellular environment maintenance [119]. A tumor can be defined as a disease in which individual cells attempt to “cheat” this highly organized system. Tumor cells increase their fitness but reduce the fitness of the whole organism [120]. It is presumed that, in order to fight tumors, multicellular organisms developed systems of communication and cell cycle control. The precise time when tumors became a threat in the history of the animal kingdom and the incidence of tumors in animals living in their natural habitats, especially in invertebrates, still remains to be resolved. Although the data are scarce and no systematic research has been done in the field, there is evidence that tumors appeared in different lineages within the animal kingdom. Besides well studied diseases in mammals, neoplasms has been reported in invertebrate deuterostomes [119] in protostomes [121, 122] and even in simple non-bilaterian animals [123–125]. The most thoroughly described non-human tumors are from vertebrates, especially farm animals and pets [126, 127] as well as other animals kept in captivity [128]. They were also identified in invertebrate animal models (*H. vulgaris*, *D. melanogaster*) but these findings should be taken with caution since laboratory breeding and culture conditions are far from those in natural habitats [125]. Therefore, it is questionable whether these organisms ever develop tumors in natural conditions. Indirect evidence of the presence of tumors in more distinct phyla also comes from the fact that marine invertebrates produce active substances that have antitumor activity on human tumor cells in culture [129]. However, it is not clear whether these substances are produced to protect the organism from potential carcinogens, or for a completely different ecological or physiological purpose. Most genes and pathways implicated in human genetic diseases and in neoplasia development and progression are highly conserved throughout evolution and can be found in early-branching metazoans such as non-bilaterians or even unicellular eukaryotes [19, 28, 130–139]. This is probably due to the fact that most human diseases developed by abusing or distorting basic cellular processes common to all living beings. This supports the idea that tumor is an ancient phenomenon [19]. However, at this point we can only speculate about the presence of tumors in the early evolution of animals. Although the homologs of tumor associated genes are present in invertebrates and even in unicellular relatives of animals, it is unclear whether the same genes relevant for neoplastic transformation in mammals are involved in the invertebrate tumors and whether these diseases are homologous. Several studies imply that this is highly probable since homologs of the key

cancer-related genes, such as *TP53* and *RAS*, are involved in neoplastic formations in invertebrates [140–143]. Tumors in invertebrates seem to rarely be malignant [144], although exceptions of this rule have been described. For instance, marine bivalves (Mollusca) form malignant neoplasms [145] as do cnidarians [146]. For a detailed review on neoplasms detected so far across the eukaryotes see Aktipis et al 2017 [119]. In his comparative study of tumorigenesis and tumor immunity in invertebrates and non-mammalian vertebrates J. Robert suggests that the progress of malignancy runs in parallel with the development of the immune system. According to this theory the increased capacity of the immune system of a highly complex organism to generate a strong and specific immune response results in selection of a vast variety of more invasive tumors [144]. It seems that the development of a highly effective vasculatory system which is found in vertebrates could also be beneficial for metastasis dissemination [147].

Our analysis suggests that the members of the third group, emerging as a vertebrate innovation, have only a few homologs in their genomes (*KISS1*, *LIFR*, *AKAP12*, *CD44*, *CDHs*, *GAS1*), possibly because they appeared after two rounds of whole genome duplication that happened at the origin of vertebrates [148]. The proteins coded by these genes are membrane bound or extracellular, which implies their role in cell–cell communication, adhesion, movement, or some other interaction with the microenvironment.

Although serving as guards against cancer dissemination and, therefore, having a crucial function in the maintenance of an organism's fitness, it is highly unlikely that the proteins in the first two peaks arose originally as metastasis suppressors, especially since metastatic tumors seem to be rare in non-vertebrate species [144]. It is more likely that their original biological function(s) were adapted in the course of evolution to fight the growing threat of malignancy. If we position neoplasms as an inevitable side effect of multicellularity that has developed in parallel with this type of organization, it is possible that some representatives of the third group emerged with the specific function—as guards against this severe and life-threatening side process. However, this is highly speculative and should be addressed by future experimental studies. It is expected that the list of metastasis suppressors might change in the future, either by the addition of new candidates or by discarding those whose function was misinterpreted. At this point we were unable to connect the evolutionary origin of specific suppressors with a specific step in the metastatic cascade. Hopefully this will be possible once the role of metastasis suppressors is more firmly established in human and other metazoans.

Acknowledgements This work was fully supported by Croatian Science Foundation projects (IP-2016-06-4021 and IP-2014-09-6400).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Res.* 2010;70:5649–69.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nat Med.* 2006;12:895–904.
3. Dezeljic M, Bosnar MH. Metastasis—recent scientific insights and challenging new therapeutic approaches. *Period Biol.* 2012;114:453–9.
4. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Res.* 2006;66:8319–26.
5. Rosengard AM, Krutzsch HC, Shearn A, et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant *Drosophila* development. *Nature.* 1989;342:1771–80.
6. Hurst DR, Welch DR. Metastasis-suppressor genes: at the interface between the environment and tumor cell growth. *Int Rev Cel Mol Bio.* 2011;286:107–80.
7. Cook LM, Hurst DR, Welch DR. Metastasis suppressors and the tumor microenvironment. *Semin Cancer Biol.* 2011;21:113–22.
8. Nwosu ZC, Ebert MP, Dooley S, et al. Caveolin-1 in the regulation of cell metabolism: a cancer perspective. *Mol Cancer.* 2016;15:71.
9. Yates A, Akanni W, Amode MR, et al. Ensembl 2016. *Nucleic Acids Res.* 2016;44:D710–6.
10. Kersey PJ, Allen JE, Armean I, et al. Ensembl genomes 2016: more genomes, more complexity. *Nucleic Acids Res.* 2016;44:D574–D80.
11. Coordinators NR. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2017;45: D12–D7.
12. Grigoriev IV, Nordberg H, Shabalov I, et al. The genome portal of the Department of Energy Joint Genome Institute. *Nucleic Acids Res.* 2012;40:D26–D32.
13. Vilella AJ, Severin J, Ureta-Vidal A, et al. EnsemblCompara GeneTrees: complete, duplication-aware phylogenetic trees in vertebrates. *Genome Res.* 2009;19:327–35.
14. Li L, Stoeckert CJ Jr., Roos DS. OrthoMCL: identification of ortholog groups for eukaryotic genomes. *Genome Res.* 2003;13:2178–89.
15. Camacho C, Coulouris G, Avagyan V, et al. BLAST+: architecture and applications. *BMC Bioinformatics.* 2009;10:421.
16. Enright AJ, Van Dongen S, Ouzounis CA. An efficient algorithm for large-scale detection of protein families. *Nucleic Acids Res.* 2002;30:1575–84.
17. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2017. <https://www.R-project.org/>.
18. Warnes GR, Bolker B, Bonebakker L, et al. gplots: Various R programming tools for plotting data. R package version 3.0.1. 2016. <https://CRAN.R-project.org/package=gplots>.
19. Domazet-Loso T, Tautz D. Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa. *BMC Biol.* 2010;8:66.
20. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. *J Natl Cancer Inst.* 1988;80:200–4.
21. Hartsough MT, Steeg PS. Nm23/nucleoside diphosphate kinase in human cancers. *J Bioenerg Biomembr.* 2000;32:301–8.
22. Hartsough MT, Morrison DK, Salerno M, et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of

- ras via a histidine protein kinase pathway. *J Biol Chem.* 2002;277:32389–99.
23. Postel EH. Multiple biochemical activities of NM23/NDP kinase in gene regulation. *J Bioenerg Biomembr.* 2003;35:31–40.
 24. Desvignes T, Pontarotti P, Fauvel C, et al. Nme protein family evolutionary history, a vertebrate perspective. *BMC Evol Biol.* 2009;9:256.
 25. Desvignes T, Pontarotti P, Bobe J. Nme gene family evolutionary history reveals pre-metazoan origins and high conservation between humans and the sea anemone, *Nematostella vectensis*. *PLoS ONE.* 2010;5:e15506.
 26. Perina D, Bosnar M, Bago R, et al. Sponge non-metastatic Group I Nme gene/protein—structure and function is conserved from sponges to humans. *BMC Evol Biol.* 2011;11:87.
 27. Bilitou A, Watson J, Gartner A, et al. The NM23 family in development. *Mol Cell Biochem.* 2009;329:17–33.
 28. Cetkovic H, Perina D, Harcet M, et al. Nme family of proteins—clues from simple animals. *N-S Arch Pharmacol.* 2015;388:133–42.
 29. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. *Cancer Res.* 2002;62:6418–23.
 30. Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. *Eur J Cancer.* 2010;46:1252–9.
 31. Samant RS, Seraj MJ, Saunders MM, et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis. *Clin Exp Metastas.* 2001;18:683–93.
 32. Stafford LJ, Vaidya KS, Welch DR. Metastasis suppressors genes in cancer. *Int J Biochem Cell B.* 2008;40:874–91.
 33. Song SL, Yuan Y, Lu JF, et al. The *Drosophila* ortholog of breast cancer metastasis suppressor gene, *dBrms1*, is critical for developmental timing through regulating ecdysone signaling. *Dev Biol.* 2013;380:344–50.
 34. Gao X, Pang J, Li LY, et al. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. *Oncogene.* 2010;29:4555–66.
 35. Yamashita N, Goshima Y. Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status. *Mol Neurobiol.* 2012;45:234–46.
 36. Kurdistani SK, Arizti P, Reimer CL, et al. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. *Cancer Res.* 1998;58:4439–44.
 37. Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. *Cancer Res.* 2000;60:749–55.
 38. Li B, Trueb B. DRG represents a family of two closely related GTP-binding proteins. *BBA-Gene Struct Expr.* 2000;1491:196–204.
 39. O'Briant KC, Bepler G. Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. *Genes Chromosomes Cancer.* 1997;18:111–4.
 40. Bepler G, O'Briant KC, Kim YC, et al. A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region. *Genomics.* 1999;55:164–75.
 41. Pitterle DM, Kim YC, Jolicoeur EM, et al. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). *Mamm Genome.* 1999;10:916–22.
 42. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. *Oncogene.* 2003;22:2135–42.
 43. Lin YW, Wu YD, Li JL, et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. *EMBO J.* 2010;29:1803–16.
 44. Liu W, Vivian CJ, Brinker AE, et al. Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell's journey. *Cancer Microenviron.* 2014;7:117–31.
 45. Zhou XF, Ma H. Evolutionary history of histone demethylase families: distinct evolutionary patterns suggest functional divergence. *BMC Evol Biol.* 2008;8:294.
 46. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. *Cancer Res.* 2002;62:6717–23.
 47. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. *Oncogene.* 2004;23:5978–85.
 48. Hickson JA, Huo DZ, Vander Griend DJ, et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. *Cancer Res.* 2006;66:2264–70.
 49. Griend DJV, Kocherginsky M, Hickson JA, et al. Suppression of metastatic colonization by the context-dependent activation of the c-jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. *Cancer Res.* 2005;65:10984–91.
 50. Hong BX, Li HY, Zhang MJ, et al. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. *Int J Cancer.* 2015;136:34–43.
 51. Goodison S, Yuan G, Sloan D, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. *Cancer Res.* 2005;65:6042–53.
 52. Kim T, Vigil D, Der C, et al. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. *Cancer Metast Rev.* 2009;28:77–83.
 53. Dong JT, Lamb PW, Rinkerschaeffter CW, et al. Kai1, a metastasis suppressor gene for prostate-cancer on human-chromosome 11p11.2. *Science.* 1995;268:884–6.
 54. White A, Lamb PW, Barrett JC. Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. *Oncogene.* 1998;16:3143–9.
 55. Bari R, Zhang YH, Zhang F, et al. Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis. *Am J Pathol.* 2009;174:647–60.
 56. Garcia-Espana A, Chung PJ, Sarkar IN, et al. Appearance of new tetraspanin genes during vertebrate evolution. *Genomics.* 2008;91:326–34.
 57. Huang SF, Yuan SC, Dong ML, et al. The phylogenetic analysis of tetraspanins projects the evolution of cell–cell interactions from unicellular to multicellular organisms. *Genomics.* 2005;86:674–84.
 58. Zhou S, Tang X, Tang F. Kruppel-like factor 17, a novel tumor suppressor: its low expression is involved in cancer metastasis. *Tumor Biol.* 2016;37:1505–13.
 59. Gumireddy K, Li AP, Gimotty PA, et al. KLF17 is a negative regulator of epithelial–mesenchymal transition and metastasis in breast cancer. *Nat Cell Biol.* 2009;11:1297–U69.
 60. Quintela-Fandino M, Arpaia E, Brenner D, et al. HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. *Proc Natl Acad Sci USA.* 2010;107:2622–7.
 61. Tanaka H, Shirkoohi R, Nakagawa K, et al. siRNA gelsolin knockdown induces epithelial–mesenchymal transition with a cadherin switch in human mammary epithelial cells. *Int J Cancer.* 2006;118:1680–91.
 62. Gremm D, Wegner A. Gelsolin as a calcium-regulated actin filament-capping protein. *Eur J Biochem.* 2000;267:4339–45.
 63. Baig RM, Mahjabeen I, Sabir M, et al. Mutational spectrum of Gelsolin and its downregulation is associated with breast cancer. *Dis Markers.* 2013;34:71–80.
 64. Yuan XL, Yu L, Li JH, et al. ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton. *Cancer Res.* 2013;73:3625–37.

65. Yuan XL, Wang WW, Li JH, et al. Gelsolin suppresses gastric cancer metastasis through inhibition of PKR-p38 signaling. *Oncotarget*. 2016;7:53459–70.
66. Tsai MH, Wu CC, Peng PH, et al. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. *J Mol Med*. 2012;90:187–200.
67. Parker BS, Ciocca DR, Bidwell BN, et al. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. *J Pathol*. 2008;214:337–46.
68. Fu Z, Smith PC, Zhang LZ, et al. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. *J Natl Cancer I*. 2003;95:878–89.
69. Zeng LC, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target. *Expert Opin Ther Target*. 2008;12:1275–87.
70. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res*. 2006;69:562–73.
71. Ohta S, Lai EW, Pang AL, et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. *Int J Cancer*. 2005;114:139–43.
72. Pulkuri SM, Patibandla S, Patel J, et al. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. *Oncogene*. 2007;26:5229–37.
73. Loffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. *Eur Respir J*. 2011;38:191–208.
74. Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metalloproteinases. *Biochem J*. 2005;386:15–27.
75. Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL, Boot-Handford RP. The evolution of the vertebrate metzincins; insights from *Ciona intestinalis* and *Danio rerio*. *BMC Evol Biol*. 2007;7:63.
76. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. *BBA-Mol Cell Res*. 2010;1803:55–71.
77. Pohar N, Godenschwege TA, Buchner E. Invertebrate tissue inhibitor of metalloproteinase: structure and nested gene organization within the synapsin locus is conserved from *Drosophila* to human. *Genomics*. 1999;57:293–6.
78. Hino M, Doihara H, Kobayashi K, et al. Caveolin-1 as tumor suppressor gene in breast cancer. *Surg Today*. 2003;33:486–90.
79. Han F, Gu DH, Chen Q, et al. Caveolin-1 acts as a tumor suppressor by down-regulating epidermal growth factor receptor-mitogen-activated protein kinase signaling pathway in pancreatic carcinoma cell lines. *Pancreas*. 2009;38:766–74.
80. Williams TM, Lisanti MP. The Caveolin genes: from cell biology to medicine. *Ann Med*. 2004;36:584–95.
81. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. *Am J Physiol*. 2005;288:C494–C506.
82. Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. *J Biol Chem*. 2004;279:51630–46.
83. Agarwal N, Adhikari AS, Iyer SV, et al. MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4. *Oncogene*. 2013;32:462–70.
84. Yan L, Singh LS, Zhang L, et al. Role of OGR1 in myeloid-derived cells in prostate cancer. *Oncogene*. 2014;33:157–64.
85. Singh LS, Berk M, Oates R, et al. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. *J Natl Cancer Inst*. 2007;99:1313–27.
86. Deuschle U, Schuler J, Schulz A, et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. *PLoS ONE*. 2012;7:e43044.
87. Stupack DG, Teitz T, Potter MD, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. *Nature*. 2006;439:95–99.
88. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. *Cytokine Growth Factor Rev*. 2008;19:325–31.
89. Sakamaki K, Imai K, Tomii K, et al. Evolutionary analyses of caspase-8 and its paralogs: deep origins of the apoptotic signaling pathways. *Bioessays*. 2015;37:767–76.
90. Bamias AT, Bai MC, Agnantis NJ, et al. Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma. *Cancer Invest*. 2003;21:333–40.
91. Murakami Y, Nobukuni T, Tamura K, et al. Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. *Proc Natl Acad Sci USA*. 1998;95:8153–8.
92. Wikman H, Westphal L, Schmid F, et al. Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. *Oncotarget*. 2014;5:3076–87.
93. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. *Int J Cancer*. 2003;107:53–59.
94. Fukuhara H, Kuramochi M, Fukami T, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. *Jpn J Cancer Res*. 2002;93:605–9.
95. Allinen M, Peri L, Kujala S, et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation. *Gene Chromosomes Cancer*. 2002;34:384–9.
96. Gobeil S, Zhu XC, Doillon CJ, et al. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. *Gene Dev*. 2008;22:2932–40.
97. Zarco N, Gonzalez-Ramirez R, Gonzalez RO, et al. GAS1 induces cell death through an intrinsic apoptotic pathway. *Apoptosis*. 2012;17:627–35.
98. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. *Mol Cancer Res*. 2011;9:1573–86.
99. Bohl CR, Harihar S, Denning WL, et al. Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. *J Mol Med*. 2014;92:13–30.
100. Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. *Cancer Res*. 2013;73:4112–22.
101. Gvozdenovic A, Arlt MJE, Campanile C, et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. *J Bone Miner Res*. 2013;28:838–47.
102. Su B, Zheng Q, Vaughan MM, et al. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. *Cancer Res*. 2006;66:5599–607.
103. Akakura S, Gelman IH. Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration, and mitogenic signaling. *J Signal Transduct*. 2012;2012:529179.
104. Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. *Nat Med*. 2012;18:1511–7.
105. Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. *J Natl Cancer I*. 1996;88:1731–7.

106. Kotani M, Detheux M, Vandenberghe A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J Biol Chem*. 2001;276:34631–6.
107. Pasquier J, Kamech N, Lafont AG, et al. Kisspeptin/kisspeptin receptors. *J Mol Endocrinol*. 2014;52:T101–T17.
108. Oda H, Takeichi M. Evolution: structural and functional diversity of cadherin at the adherens junction. *J Cell Biol*. 2011;193:1137–46.
109. Geiger TR, Peeper DS. Metastasis mechanisms. *BBA-Rev Cancer*. 2009;1796:293–308.
110. Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. *Int J Biochem Cell Biol*. 2009;41:349–69.
111. Thiollay S, Rinker-Schaeffer CW. Thinking outside the box: using metastasis suppressors as molecular tools. *Semin Cancer Biol*. 2011;21:89–98.
112. Timoshevskiy VA, Herdy JR, Keinath MC, et al. Cellular and molecular features of developmentally programmed genome rearrangement in a vertebrate (Sea Lamprey: *Petromyzon marinus*). *PLoS Genet*. 2016;12:e1006103.
113. Smith JJ, Kuraku S, Holt C, et al. Sequencing of the sea lamprey (*Petromyzon marinus*) genome provides insights into vertebrate evolution. *Nat Genet*. 2013;45:415–21.
114. Cutter AD, Dey A, Murray RL. Evolution of the *Caenorhabditis elegans* genome. *Mol Biol Evol*. 2009;26:1199–234.
115. Sakamaki K, Shimizu K, Iwata H, et al. The apoptotic initiator caspase-8: its functional ubiquity and genetic diversity during animal evolution. *Mol Biol Evol*. 2014;31:3282–301.
116. Golstein P, Aubry L, Levraud J-P. Cell-death alternative model organisms: why and which? *Nat Rev Mol Cell Biol*. 2003;4:798–807.
117. Domazet-Loso T, Tautz D. An ancient evolutionary origin of genes associated with human genetic diseases. *Mol Biol Evol*. 2008;25:2699–707.
118. Grosberg RK, Strathmann RR. The evolution of multicellularity: a minor major transition? *Annu Rev Ecol Evol Syst*. 2007;38:621–54.
119. Aktipis CA, Boddy AM, Jansen G, et al. Cancer across the tree of life: cooperation and cheating in multicellularity. *Philos Trans R Soc Lond B Biol Sci*. 2015;370:20140219.
120. Aktipis CA, Nesse RM. Evolutionary foundations for cancer biology. *Evol Appl*. 2013;6:144–59.
121. Stephan F. Spontaneous tumors in the planarian *Dugesia tigrina*. *C R Seances Soc Biol Fil*. 1962;156:920–2.
122. Schaeffer DJ. Planarians as a model system for in vivo tumorigenesis studies. *Ecotoxicol Environ Saf*. 1993;25:1–18.
123. Kaczmarek LT. Coral disease dynamics in the central Philippines. *Dis Aquat Organ*. 2006;69:9–21.
124. Peters EC, Halas JC, McCarty HB. Calicoblastic neoplasms in acropora-palmata, with a review of reports on anomalies of growth and form in corals. *J Natl Cancer Inst*. 1986;76:895–912.
125. Domazet-Loso T, Klimovich A, Anokhin B, et al. Naturally occurring tumours in the basal metazoan hydra. *Nat Commun*. 2014;5:4222.
126. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100:57–70.
127. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–74.
128. Griner LA. Pathology of zoo animals: a review of necropsies conducted over a fourteen year period at the San Diego Zoo and San Diego Wild Animal Park. San Diego, CA: Zoological Society of San Diego, USA; 1983. i–xliii, p 1–607.
129. Halim H, Chunhacha P, Suwanborirux K, et al. Anticancer and antimetastatic activities of renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells. *Anticancer Res*. 2011;31:193–201.
130. Cetkovic H, Grebenjuk VA, Muller WE, et al. Src proteins/src genes: from sponges to mammals. *Gene*. 2004;342:251–61.
131. Cetkovic H, Mikoc A, Muller WE, Gamulin V. Ras-like small GTPases form a large family of proteins in the marine sponge *Suberites domuncula*. *J Mol Evol*. 2007;64:332–41.
132. Cetkovic H, Muller IM, Muller WEG, et al. Characterization and phylogenetic analysis of a cDNA encoding the Fes/FER related, non-receptor protein-tyrosine kinase in the marine sponge *Sycon raphanus*. *Gene*. 1998;216:77–84.
133. Cetkovic H, Muller WE, Gamulin V. Bruton tyrosine kinase-like protein, BtkSD, is present in the marine sponge *Suberites domuncula*. *Genomics*. 2004;83:743–5.
134. Harcet M, Lukic-Bilela L, Cetkovic H, et al. Identification and analysis of cDNAs encoding two nucleoside diphosphate kinases (NDPK/Nm23) from the marine sponge *Suberites domuncula*. *Croat Chem Acta*. 2005;78:343–848.
135. Harcet M, Roller M, Cetkovic H, et al. Demosponge EST sequencing reveals a complex genetic toolkit of the simplest metazoans. *Mol Biol Evol*. 2010;27:2747–56.
136. Perina D, Bosnar MH, Mikoc A. Characterization of Nme6-like gene/protein from marine sponge *Suberites domuncula*. *N-S Arch Pharmacol*. 2011;384:451–60.
137. Perina D, Cetkovic H, Harcet M, et al. The complete set of ribosomal proteins from the marine sponge *Suberites domuncula*. *Gene*. 2006;366:27–284.
138. Perina D, Korolija M, Hadzija MP, et al. Functional and structural characterization of FAU gene/protein from marine sponge *Suberites domuncula*. *Mar Drugs*. 2015;13:4179–96.
139. Perina D, Korolija M, Roller M, et al. Over-represented localized sequence motifs in ribosomal protein gene promoters of basal metazoans. *Genomics*. 2011;98:56–63.
140. Bottger S, Jerszyk E, Low B, et al. Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53. *Cancer Res*. 2008;68:777–82.
141. Muttray AF, O'Toole TF, Morrill W, et al. An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic *Mytilus trossulus* haemocytes. *Comp Biochem Phys B*. 2010;156:298–308.
142. Martin-Gomez L, Villalba A, Carballal MJ, et al. Identification of relevant cancer related-genes in the flat oyster *Ostrea edulis* affected by disseminated neoplasia. *Mar Biotechnol*. 2013;15:159–74.
143. Ruiz P, Diaz S, Orbea A, et al. Biomarkers and transcription levels of cancer-related genes in cockles *Cerastoderma edule* from Galicia (NW Spain) with disseminated neoplasia. *Aquat Toxicol*. 2013;136:101–11.
144. Robert J. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. *Dev Comp Immunol*. 2010;34:915–25.
145. Carballal ML, Barber BJ, Iglesias D, et al. Neoplastic diseases of marine bivalves. *J Invertebr Pathol*. 2015;131:83–106.
146. Peters EC, Halas JC, McCarty HB. Calicoblastic neoplasms in *Acropora palmata*, with a review of reports on anomalies of growth and form in corals. *J Natl Cancer Inst*. 1986;76:895–912.
147. Monahan-Earley R, Dvorak AM, Aird WC. Evolutionary origins of the blood vascular system and endothelium. *J Thromb Haemost*. 2013;11:46–66.
148. Panopoulou G, Poustka AJ. Timing and mechanism of ancient vertebrate genome duplications—the adventure of a hypothesis. *Trends Genet*. 2005;21:559–67.